The Clinical Desire for Pressurized Intraperitoneal Aerosol Chemotherapy in South Korea: An Electronic Survey-based Study.
Anticancer Res
; 42(1): 363-371, 2022 Jan.
Article
en En
| MEDLINE
| ID: mdl-34969746
ABSTRACT
BACKGROUND/AIM:
To evaluate the clinical desire for pressurized intraperitoneal aerosol chemotherapy (PIPAC) in South Korea. PATIENTS ANDMETHODS:
We performed an online survey on surgical oncologists between November and December 2019 using a questionnaire consisting of 20 questions.RESULTS:
A total of 164 respondents answered the questionnaire. Among those specialized in ovarian cancer, pseudomyxoma peritonei, and malignant mesothelioma 41.7-50% preferred PIPAC for the curative treatment of primary diseases, whereas 32.7-33.3% majoring in colorectal and hepatobiliary cancers chose it for the palliative treatment of recurrent diseases. Furthermore, 66.7-95.2% considered PIPAC appropriate for the cancers they specialized in, and 76-78.7% expected a treatment response of more than 50% and considered grade 1 or 2 complications acceptable. Most respondents answered the reasonable costs to purchase and implement PIPAC once at between 1,000,000-5,000,000 South Korean Won (KRW).CONCLUSION:
Most Korean surgical oncologists expected relatively high tumor response rates with minor toxicities through the repeated implementation of PIPAC.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
Problema de salud:
1_financiamento_saude
Asunto principal:
Neoplasias Ováricas
/
Seudomixoma Peritoneal
/
Oncólogos
/
Mesotelioma Maligno
/
Infusiones Parenterales
Tipo de estudio:
Health_economic_evaluation
/
Qualitative_research
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Anticancer Res
Año:
2022
Tipo del documento:
Article